Return to Home

Masimo Corporation

MASI

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
October 23, 2023

Days Left:
-352

calendar

Masimo Corporation Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Allegations

According to the complaint, defendants provided investors with material information concerning Masimo’s revenue and sales for the second quarter of fiscal 2023 and expected revenue for the full-year 2023. Defendants’ statements included, among other things, Masimo’s ability to deliver clinically proven new products to the healthcare markets thereby supporting defendants’ decision to forecast revenue of $550 million to $565 million for the quarter and increase its earnings-per-share estimates to between $3.59 per share and $3.69 per share. Defendants’ statements in this regard prompted an immediate and dramatic increase in the price of Masimo’s common stock. From a closing price of $167.31 per share on February 28, 2023 at the start of the Class Period, Masimo’s stock price climbed to $184.97 per share the following day on March 1, 2023 on unusually high volume. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts. On July 17, 2023 Masimo issued a press release announcing its second quarter 2023 earnings. Defendants announced lower than expected revenue for the second quarter of fiscal 2023 and preliminarily decreased full-year revenue estimates for both healthcare and non-healthcare segments. On this news, the price of Masimo’s common stock declined dramatically. From a closing market price of $147.16 per share on July 17, 2023, Masimo’s stock price fell to $117.73 per share on July 18, 2023, a decline of nearly 20% in the span of just a single day.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Masimo purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Masimo during the relevant time frame, you have until October 23, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Find More Cases

Ticker Symbol Company Name Join Deadline
CXM Sprinklr, Inc. October 15, 2024 Join
STLA Stellantis N.V. October 15, 2024 Join
SYM Symbotic Inc. October 15, 2024 Join
EXTR Extreme Networks, Inc. October 15, 2024 Join
PDD PDD Holdings Inc. f/k/a Pinduoduo Inc. October 15, 2024 Join
ARDX Ardelyx, Inc. October 15, 2024 Join
OFIX Orthofix Medical Inc. October 21, 2024 Join
DXCM DexCom, Inc. October 21, 2024 Join
SPIR Spire Global, Inc. October 21, 2024 Join
STM STMicroelectronics N.V. October 22, 2024 Join
DAVA Endava plc October 25, 2024 Join
MEI Methode Electronics, Inc. October 25, 2024 Join
SAGE Sage Therapeutics, Inc. October 28, 2024 Join
VERV Verve Therapeutics, Inc. October 28, 2024 Join
SBUX Starbucks Corporation October 28, 2024 Join
OM Outset Medical, Inc. October 28, 2024 Join
SMCI Super Micro Computer, Inc. October 29, 2024 Join
ZI ZoomInfo Technologies Inc. November 04, 2024 Join
WBTN WEBTOON Entertainment Inc. November 04, 2024 Join
GTLB GitLab Inc. November 04, 2024 Join
GTLB GitLab Inc. November 04, 2024 Join
AGEN Agenus Inc. November 05, 2024 Join
NFE New Fortress Energy Inc. November 18, 2024 Join
MGX Metagenomi, Inc. November 25, 2024 Join
BMBL Bumble Inc. November 25, 2024 Join